한국어
English
日本語
中文(简体)
Imbruvica Capsule 140mg (Ibrutinib)
140mg
Hard capsule · Prescription medication
(Co., Ltd.) Janssen Korea
Ibrutinib acts as a targeted anticancer agent used for the treatment of blood cancers.
MFDS ingredient code M285632
Ibrutinib is a targeted anticancer agent component that selectively inhibits Bruton's tyrosine kinase (BTK). It is primarily used for the treatment of specific blood cancers such as chronic lymphocytic leukemia.
Ibrutinib blocks the activity of the BTK enzyme within cancer cells, disrupting the signaling for growth and survival of cancer cells. As a result, cancer cells are unable to proliferate and undergo apoptosis.
Approved uses differ by product. Check each product's information for its actual use.
Unlike traditional chemotherapy, Ibrutinib targets specific enzymes to reduce side effects and enhance therapeutic efficacy. It is characterized by its formulation in a micronized form, which improves the absorption rate in the body.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
Product approval information is based on drug information provided by the Ministry of Food and Drug Safety.
Ingredient and class descriptions are not part of MFDS data and were written separately by Cashdoc.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.